Profound Medical Corp. (TSE:PRN) Director Buys C$61,380.93 in Stock

Profound Medical Corp. (TSE:PRN) Director Arthur Lee Rosenthal purchased 9,200 shares of the stock in a transaction that occurred on Friday, May 16th. The stock was acquired at an average cost of C$6.67 per share, with a total value of C$61,380.93.

Arthur Lee Rosenthal also recently made the following trade(s):

• On Thursday, May 15th, Arthur Lee Rosenthal purchased 8,360 shares of Profound Medical stock. The stock was acquired at an average cost of C$6.20 per share, with a total value of C$51,833.50.

Profound Medical Stock Performance

Shares of PRN opened at C$6.63 on Friday. The company has a market capitalization of C$15.45 million, a price-to-earnings ratio of -3.44 and a beta of 1.22. Profound Medical Corp. has a 52-week low of C$5.58 and a 52-week high of C$15.75. The stock has a 50 day moving average price of C$7.48 and a 200 day moving average price of C$9.38. The company has a quick ratio of 14.98, a current ratio of 6.12 and a debt-to-equity ratio of 20.05.

Analysts Set New Price Targets

Separately, Raymond James downgraded Profound Medical from a “strong-buy” rating to a “moderate buy” rating in a report on Friday, May 9th.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.